旋磨設備市場——增長、趨勢和預測 (2023-2028)
市場調查報告書
商品編碼
1189875

旋磨設備市場——增長、趨勢和預測 (2023-2028)

Atherectomy Devices Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 121 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內,旋磨設備市場預計將以 6.03% 左右的複合年增長率增長。

與許多其他市場一樣,市場也受到了 COVID-19 大流行的影響。 各種心血管手術和非必要治療已被推遲。 2022 年 3 月,發表在《胸外科年鑑》上的研究結果分析了 717,103 名成人心臟手術患者和超過 2000 萬名 COVID-19 患者。據說有所減少。 中大西洋地區受最初 COVID-19 激增的影響最大,總體病例下降 69.7%,部分病例下降 80.0%。 在大西洋中部和新英格蘭地區,觀察到的孤立冠狀動脈搭橋手術的死亡率與 COVID 之前相比顯著增加了 1.48 倍(增加 148%)。 在最初的 COVID-19 激增之後,全國心臟手術病例數沒有恢復到基線水平,表明與 COVID-19 相關的心臟手術患者數量不足。 動脈粥樣硬化斑塊切除術是一種清除心臟阻塞動脈的手術。 心臟手術還將包括粥樣斑塊切除術。 因此,整個市場都受到了影響。 因此,在全球範圍內,隨著 COVID-19 限制的放寬,市場有望在幾年內獲得牽引力並全面反彈。

粥樣斑塊旋切術設備市場的主要驅動因素是人們越來越偏愛微創手術。 擴大微創手術的研究也是推動市場增長的因素之一。 2021 年 10 月,經皮冠狀動脈介入治療 (PCI) 的持續進步促使外科醫生降低外科血運重建手術的侵入性,導致微創心臟手術 (MICS) 技術的發展。在過去幾十年中得到了廣泛擴展,根據發表在 Elsevier Journal 上的一項研究。 MICS 的主要目標是避免胸骨切開術、減少術後輸血、減少通氣時間、減少重症監護和住院時間、減少術後疼痛以及促進恢復正常活動。 由於這些優勢,MICS 的採用正在增加,市場有望增長。

此外,持續的產品開發和商業化有望推動市場增長。 2021 年 11 月,皇家飛利浦將在美國奧蘭多推出包括 Nexcimerlaser 系統在內的外周和冠狀動脈應用。 新的飛利浦激光系統 -Nexcimer - 為冠狀動脈和外周動脈粥樣硬化斑塊切除術和導線拔除手術提供即插即用的簡單性。 該系統是唯一接受用於 ISR 粥樣斑塊切除術的臨床數據 I 級導管的系統,並且還與導線提取兼容(去除心臟周圍的起搏器和除顫器導線)。

在當前醫療、醫療費用和保險制度改革的趨勢下,患者及其護理人員必須將支付方和提供方聯繫起來,以應對飆升的醫療費用。 報銷和保險範圍改革將增加在保險範圍內選擇治療的機會。 因此,增加贖回將增加未來一段時間的市場增長。 2022 年,醫療保險和醫療補助服務中心 (CMS) 將增加外周血管內碎石術 (IVL) 手術的報銷。 涉及血運重建的手術,不包括血管內、開放或經皮、腿部動脈、脛骨/腓骨;包括在同一血管內進行的血管成形術和血管內碎石術(CPT 代碼:C9764)您將收到 10258 美元。 同樣,涉及血運重建、血管內治療、開放或經皮手術、除脛骨/腓骨外的下肢動脈的手術;如果包括內部血管成形術,將支付 16,402 美元(CPT 代碼:C9765)。 此外,非脛骨/腓骨下肢動脈(涉及血管內、開放或經皮再灌注的過程)、血管內碎石術和腔內支架置入術(多個)和粥樣斑塊切除術(同一血管內的血管成形術)(CPT 代碼:C9767),您將支付 16,402 美元。 因此,上述所有因素預計將在預測期內提振市場。

但是,嚴格的監管情景可能會在預測期內抑制市場增長。

主要市場趨勢

在預測期內,定向斑塊切除術部分將在調查的市場中佔有重要的市場份額

在預測期內,定向旋磨術預計將比其他產品增長更多,因為它具有某些優勢,例如降低治療成本和提高效率。 越來越多地採用微創動脈粥樣硬化斑塊切除術可能會增加對斑塊切除術設備的需求。 根據 Krishna J. Rocha-Singh 等人於 2021 年 6 月發表的一項研究,在藥物塗層球囊 (DCB) 血管成形術之前通過定向粥樣斑塊切除術 (DA) 去除斑塊與有症狀的嚴重鈣化有關。它被發現是股膕動脈疾病患者臨時支架率低的安全有效治療方法。 因此,此類研究有望進一步促進 DA 系統的使用,從而有望推動所調查領域的增長。

主要市場參與者的戰略舉措,如產品發布、併購和合作夥伴關係,預計也將有助於市場增長。 例如,2021 年 8 月,美敦力 (Medtronic) 向 USFDA 提交了一份申請,要求批准 TurboHawk Plus 定向斑塊切除術系統,這是一種較舊且已基本淘汰的斑塊切除術設備的更新版本。 該裝置有助於在外周動脈疾病 (PAD) 干預期間增加粥樣斑塊切除術。 此外,2021 年 11 月,Avinger Inc .獲得了美國 FDA 的 510(k) 許可,用於其 Pantherisimage 引導的粥樣斑塊切除術系統的新臨床適應症。 該批准允許該公司直接銷售 Pantheris 用於治療下肢動脈支架內再狹窄( ISR )。

因此,由於手術和產品創新的數量不斷增加,因此在本研究的預測期內,定向粥樣斑塊切除術系統部分有望實現增長。

北美將佔據很大的市場份額,預計在預測期內也會如此

預計北美將佔據很大的市場份額。 旋磨系統的報銷增加,醫護人員採用旋磨系統,大量外周動脈疾病和冠狀動脈疾病患者,臨床試驗(為了評估

根據疾病預防控制中心 2022 年 2 月的更新,無論性別、種族或民族如何,心髒病都是導緻美國死亡的主要原因,而冠心病是最常見的心髒病類型。(CHD) 或冠心病動脈疾病,其中冠狀動脈變窄和在其壁中形成膽固醇堵塞可導致中風和心髒病發作。 因此,由於心髒病患病率上升,該地區對斑塊切除手術的需求預計將增加,預計這將在預測期內推動監測市場的增長。

合適的報銷場景和大量的FDA批准的設備是這一優勢的主要原因。 例如,2021 年 10 月,BD(Becton, Dickinson & Company)宣布已獲得美國 FDA 的 510(k) 許可,用於擴大 Rotarex Atherectomy 系統的適應症。 此外,2021 年 11 月,皇家飛利浦宣佈在北美首次亮相新的外周和冠狀動脈應用,包括 IntraSight Mobile 系統和 Nexcimer 激光系統。

因此,上述所有因素預計將在預測期內提振該地區的市場。

競爭格局

由於許多跨國公司的存在,旋磨術市場競爭相當激烈。 例如,Abbott Laboratories、B. Braun SE、Boston Scientific、CR Bard、Cardinal Health Inc、Koninklijke Philips NV、Medtronic PLC 和 Terumo Corporation 在全球範圍內提供產品。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 持續的產品開發和商業化
    • 成熟市場中有利的醫療報銷方案
    • 對微創手術的需求不斷增長
  • 市場製約因素
    • 嚴格的監管場景
    • 缺乏訓練有素的外科醫生
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模 - 百萬美元)

  • 按產品分類
    • 定向旋磨系統
    • 眼眶運動系統
    • 光消融(激光)旋磨系統
    • 旋磨系統
  • 通過使用
    • 外周血管
    • 心血管
    • 神經血管
  • 最終用戶
    • 醫院、手術中心
    • 門診中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • B. Braun SE
    • Boston Scientific Corporation
    • Becton, Dickinson and Company
    • Cardinal Health Inc.
    • Koninklijke Philips NV
    • Medtronic
    • RA Medical Systems
    • Terumo Corporation
    • Cardiovascular Systems Inc.
    • Biomerics LLC
    • AngioDynamics Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 60425

The atherectomy devices market is expected to record a CAGR of about 6.03% during the forecast period 2022-2027.

Like many other markets, the market was impacted by the COVID-19 pandemic. Various cardiovascular procedures and non-essential treatments were postponed. In March 2022, a research study was published in the Annals of Thoracic Surgery, which analyzed 717,103 adult cardiac surgery patients and more than 20 million COVID-19 patients stated that there was a 52.7% reduction in adult cardiac surgery volume and a 65.5% reduction in elective cases. The Mid-Atlantic region was most affected by the first COVID-19 surge, with a 69.7% reduction in overall case volume and an 80.0% reduction in elective cases. In the Mid-Atlantic and New England regions, the observed-to-expected mortality for isolated coronary bypass increased as much as 1.48 times (148% increase) pre-COVID rates. After the first COVID-19 surge, nationwide cardiac surgical case volumes did not return to baseline, indicating a COVID-19-associated deficit in cardiac surgery patients. Atherectomy is a procedure used to clear out clogged heart arteries. The cardiac surgeries would also include atherectomy surgeries. Hence, the market was affected across the globe. Hence, with the easing of COVID-19 restrictions, worldwide, the market gained traction and is expected to bounce back to its full potential over the years.

The market for atherectomy devices is majorly driven by the increasing preference for minimally invasive surgeries. Research studies about the expansion of minimally invasive surgeries are another factor that drives the market growth. In October 2021, a research study was published in Elsevier Journal, stating that continuous progress in percutaneous coronary intervention (PCI) has inspired surgeons to reduce the invasiveness of surgical revascularization techniques, resulting in the development of minimally invasive cardiac surgery (MICS) procedures, which have widely expanded over the past couple of decades. The main goals of MICS are to avert any form of sternotomy, reduce postoperative blood product transfusion, shorten ventilation times, reduce intensive care and hospital stays, diminish postoperative pain, and accelerate the return to normal activities. Hence, due to such advantages of MICS, there will be growth in the adoption of such surgeries which would increase the market growth.

Additionally, continuous product development and commercialization are expected to propel the growth of the market. In November 2021, Royal Philips launched peripheral and coronary artery applications, including the Nexcimerlaser system in Orlando, United States. The new Philips Laser System - Nexcimer- offers plug-and-play simplicity for coronary and peripheral atherectomy and lead extraction procedures. It is the only system compatible with catheters with Level I clinical data for ISR atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart).

In the current trend of healthcare, reimbursement, and coverage reform, payer and provider consolidation for escalating healthcare costs are essential for patients and their caregivers. ​Reimbursement and coverage reform enhances the chances of opting for the treatment if it is covered. Hence, increasing reimbursement would increase the market growth in the upcoming period. In 2022, the Centers for Medicare and Medicaid Services (CMS), has increased reimbursement for peripheral intravascular lithotripsy (IVL) procedures. Procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel (s) (CPT code: C9764) will receive USD 10,258. Similarly, a procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessels, (CPT code: C9765) will receive USD 16,402. Furthermore, processes including revascularization, endovascular, open or percutaneous, lower extremity arteries), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, including angioplasty within the same vessels, when performed (CPT code: C9767) will receive USD 16,402. Thus, all the above-mentioned factors are expected to boost the market over the forecast period.

However, the stringent regulatory scenarios may restrain the market growth over the forecast period.

Key Market Trends

Directional Atherectomy Segment Holds a Significant Market Share in the Studied Market Over the Forecast Period

The directional atherectomy segment of the market is expected to witness significant growth in the forecast period over other products as it offers certain advantages such as low treatment cost, improved efficiency, etc. The increasing adoption of minimally invasive atherectomy procedures may boost the demand for atherectomy devices. According to a research study published by Krishna J. Rocha-Singh et. al., in June 2021, plaque removal with directional atherectomy (DA) before drug-coated balloon (DCB) angioplasty is a safe and effective treatment technique with a low provisional stent rate in patients with symptomatic severely calcified femoropopliteal artery disease. Thus, research studies like these are further expected to promote the usage of DA systems which is anticipated to fuel growth in the studied segment.

The strategic initiatives taken by key market players such as product launches, mergers and acquisitions, and partnerships are also expected to contribute to market growth. For instance, in August 2021, Medtronic submitted an application to the USFDA for the approval of the TurboHawk Plus Directional Atherectomy System, an updated version of its older and largely phased-out atherectomy device. This device will facilitate increased atherectomy procedures during Peripheral Arterial Disease (PAD) interventions. Additionally, in November 2021, Avinger Inc. received 510(k) approval from United States FDA for the Pantherisimage-guided atherectomy system's new clinical indication. This clearance allows the company to directly market Pantheris forthe treatment of in-stent restenosis (ISR) in the lower extremity arteries.

Therefore, overall, with the growing number of surgeries, and product innovation, the directional atherectomy systems segment is expected to grow during the forecast period of the study.

North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period

North America is expected to hold a significant share of the market. Factors such as increasing availability of reimbursements for atherectomy systems, adoption of atherectomy systems among medical professionals, the large patient population of peripheral and coronary artery diseases, and an increasing number of clinical trials (that aim to evaluate the therapeutic efficacy of atherectomy systems in specific disease treatment) are driving the growth of the North American atherectomy devices market.

According to the February 2022 update of the CDC, in United States, heart diseases are the leading cause of death irrespective of gender, race, or ethnicity and the most common type of heart disease is coronary heart disease (CHD) or coronary artery disease in which coronary arteries become too narrow or cholesterol blockages develop in the walls, leading to stroke or heart attack. Thus, due to the rising prevalence of heart diseases, the demand for atherectomy procedures is expected to increase in the region which is anticipated to fuel growth in the studied market over the forecast period.

A suitable reimbursement scenario and a high number of FDA-approved devices are the key reasons for this dominance. For instance, in October 2021, BD (Becton, Dickinson and Company) announced it has received 510(k) clearance for expanded indications from the U.S. FDA for the Rotarex Atherectomy System. Additionally, in November 2021, Royal Philips announced the North American debut of new peripheral and coronary artery applications, including the IntraSight Mobile system and the Nexcimer laser system.

Thus, all above mentioned factors expected to boost the market in the region over the forecast period.

Competitive Landscape

The atherectomy devices market is moderately competitive, with the presence of many global players. For instance, Abbott Laboratories, B. Braun SE, Boston Scientific, CR Bard, Cardinal Health Inc., Koninklijke Philips NV, Medtronic PLC, Terumo Corporation, etc., are offering their products across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Continuous Product Development and Commercialization
    • 4.2.2 Favourable Medical Reimbursement Scenario in Mature Markets
    • 4.2.3 Growing Demand for Minimally Invasive Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Lack of Well-trained Surgeons
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product
    • 5.1.1 Directional Atherectomy Systems
    • 5.1.2 Orbital Atherectomy Systems
    • 5.1.3 Photo-ablative (Laser) Atherectomy Systems
    • 5.1.4 Rotational Atherectomy Systems
  • 5.2 By Application
    • 5.2.1 Peripheral Vascular Applications
    • 5.2.2 Cardiovascular Applications
    • 5.2.3 Neurovascular Applications
  • 5.3 By End User
    • 5.3.1 Hospitals and Surgical Centers
    • 5.3.2 Ambulatory Care Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 B. Braun SE
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Cardinal Health Inc.
    • 6.1.6 Koninklijke Philips NV
    • 6.1.7 Medtronic
    • 6.1.8 RA Medical Systems
    • 6.1.9 Terumo Corporation
    • 6.1.10 Cardiovascular Systems Inc.
    • 6.1.11 Biomerics LLC
    • 6.1.12 AngioDynamics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS